9 stories mentioning HKG:2256Updated just now
Every FINWIRES story that references HKG:2256, newest first.
Abbisko Cayman (HKG:2256) said its investigational drug lavengratinib showed positive preliminary efficacy results in a Phase 2 study for children with achondroplasia, according to an exchange filing.In the first and lowest-dose cohort, children aged 6 and older who received 0.064 mg/kg once daily for 27 weeks achieved a mean annualized height velocity increase of 2.4 centimeters per year, with a 100% responder rate.
Abbisko Cayman (HKG:2256) said its subsidiary has dosed the first patient in a Phase I trial of ABSK211, an oral pan-KRAS inhibitor for advanced solid tumors with KRAS alterations.The trial will evaluate the drug's safety, tolerability, efficacy and pharmacokinetics, according to a Sunday Hong Kong bourse filing.Shares of the company fell nearly 4% in recent trade.
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics' investigational new drug application for ABSK211 was cleared by China's National Medical Products Administration.The drug candidate is for the treatment of patients with advanced solid tumors harboring KRAS alterations, according to a Wednesday Hong Kong bourse filing.
Abbisko Cayman (HKG:2256) said its subsidiary, Abbisko Therapeutics, received U.S. Food and Drug Administration investigational new drug clearance for ABSK211, according to a Hong Kong bourse filing Monday.ABSK211 is an oral, highly potent and selective small-molecule pan-KRAS inhibitor being developed for the treatment of patients with advanced solid tumors harboring KRAS alterations.Abbisko's shares rose 1% in recent trade.
Abbisko Cayman (HKG:2256) said its subsidiary, Abbisko Therapeutics, entered into a strategic collaboration with AstraZeneca to jointly develop a combination therapy for non-small cell lung cancer, according to a Thursday Hong Kong bourse filing.The companies will evaluate Abbisko's oral PD-L1 inhibitor, lumipodlin, in combination with AstraZeneca's Tagrisso in a Phase 1/2 clinical trial involving patients with EGFR-mutated and PD-L1-positive locally advanced or metastatic non-small cell lung cancer.Abbisko will lead the Phase 2 study, while both companies will share responsibility for conducting the clinical trial.
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics entered a research and license partnership with Eli Lilly to develop new medicines, according to a Wednesday filing with the Hong Kong bourse.The firm will receive an upfront payment, as well as milestone payments totaling up to $1.9 billion. The company will also received royalties on drugs commercialized as a result of the partnership.
Abbisko Cayman (HKG:2256) expanded its collaboration with Eli Lilly through a new research and licensing agreement covering multiple drug targets, according to a Wednesday Hong Kong bourse filing.Under the agreement, Abbisko will receive an upfront payment and is eligible for development, regulatory, and commercial milestone payments totaling up to about $1.9 billion, along with tiered royalties on future product sales.The company will conduct drug discovery and early-stage development activities for therapeutic programs selected by Lilly, leveraging its discovery platform and research capabilities.The agreement follows a 2022 collaboration between the companies focused on the discovery, development, and potential commercialization of a novel small-molecule therapy.
Abbisko (HKG:2256) completed a HK$522.5 million share offering, according to a Hong Kong bourse filing Tuesday.The drug company's shares fell over 2% in afternoon trade Wednesday.The firm sold 42.9 million shares priced at HK$12.18 each to raise funds for the research and development of cancer and non-cancer drug candidates.The shares represent 5.99% of the company's enlarged share capital.
Abbisko (HKG:2256) said it was looking to raise nearly HK$523 million via a share offering, according to a Hong Kong bourse filing Tuesday.The firm is seeking investors for 42.9 million shares priced at HK$12.18 each to raise funds for the research and development of cancer and non-cancer drug candidates.The shares represent 6.37% of the company's issued share capital and 5.99% as enlarged by the sale.
